Free shipping on all orders over $ 500

Axitinib

Cat. No. M1658
Axitinib Structure
Synonym:

AG-013736

Size Price Availability Quantity
10mM*1mL in DMSO USD 45  USD50 In stock
50mg USD 40.5  USD45 In stock
100mg USD 63  USD70 In stock
200mg USD 81  USD90 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Axitinib blocked phosphorylation of VEGFR-2 and VEGFR-3 with average IC50s of 0.2 and 0.1 to 0.3 nM.Axitinib (also known as AG013736) is a small molecule tyrosine kinase inhibitor.It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in xenograft models and has been successful in trials with renal cell carcinoma (RCC) and several other tumor types.

Product Citations
Customer Product Validations & Biological Datas
Source Int J Cancer (2017) . Figure 6. Axitinib (20 mg/kg, Abmole Bioscience)
Method
Cell Lines Hmga2/T mice
Concentrations 20mg/kg
Incubation Time 6 weeks
Results Together, these results show that, while bromocriptine and/or axitinib were able to correct structuralabnormalities of tumoral vessels with a similar efficacy, only the combination treatment restored their function.
Source Int J Cancer (2017) . Figure 5. Axitinib (20 mg/kg, Abmole Bioscience)
Method
Cell Lines Hmga2/T mice
Concentrations 20mg/kg
Incubation Time 6 weeks
Results Analysis of pituitary vasculature in various conditions and morphometric measurements of blood vessels demonstrate that D2R agonist or axitinib had an equivalent capacity to improve structural defects present in tumoral blood vessels and that the combination treatment did not lead to a significant advantage.
Source Int J Cancer (2017) . Figure 4. Axitinib (20 mg/kg, Abmole Bioscience)
Method
Cell Lines Hmga2/T mice
Concentrations 20mg/kg
Incubation Time 6 weeks
Results Importantly, the expression of Angpt1 and Prok1, which was upregulated in response to bromocriptine treatment, was unchanged and remained low after axitinib treatment (Fig. 4d).
Protocol
Cell Experiment
Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cell lines
Preparation method MTS cell proliferation assay
HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cell lines were seeded at 5,000 cells per well in a 96-well plate and left to settle overnight in EMBV R-2 or DMEM with 10% fetal calf serum. The cells were treated with axitinib at concentrations ranging from 1 nmol/l to 10 lmol/l. Cell viability was determined after 72 hr using MTS tetrazolium substrate (CellTiter 96 Aqueous One Solution Cell Proliferation Assay; Promega Corporation, Charbonnieres, France) and colorimetric measurement at 490 nm in an automatic plate reader (Elx808; Fisher Bioblock Scientific SAS, Illkirch, France). IC50 values were calculated using GraphPadV R Prism software (version 3.00).
Concentrations 1 nmol/l to 10 lmol/l
Incubation time 72 hr
Animal Experiment
Animal models IGR-N91 xenografts with female SPF-Swiss athymic nude mice at 6–8 weeks of age
Formulation 0.5% CMC
Dosages 30 mg/kg BID for 2 weeks
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 386.47
Formula C22H18N4OS
CAS Number 319460-85-0
Purity 99.80%
Solubility DMSO
Storage at -20°C
References

Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael et al. Clin Adv Hematol Oncol. 2012 May;10(5):307-14. PMID: 22706540.

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Pithavala et al. Cancer Chemother Pharmacol. 2012 Jul;70(1):103-12. PMID: 22644797.

Related VEGFR/PDGFR Products
TAS-115 mesylate

TAS-115 (Pamufetinib) mesylate inhibited the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors.

Ningetinib

Ningetinib is a potent, orally bioavailable tyrosine kinase inhibitor for Axl, VEGFR2 and c-Met with IC50 values of <1.0, 1.9 and 6.7 nM, respectively.

Tanshinone IIA

Tanshinone IIA suppresses angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2. *The compound is unstable in solutions, freshly prepared is recommended.

AC710

AC710 is a potent, selective and orally active platelet-derived growth factor receptor-family (PDGFR) kinase inhibitor with potential anticancer activity.

Sitravatinib

Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Axitinib, AG-013736 supplier, VEGFR/PDGFR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.